Concord Wealth Partners Astrazeneca PLC Transaction History
Concord Wealth Partners
- $673 Million
- Q2 2025
A detailed history of Concord Wealth Partners transactions in Astrazeneca PLC stock. As of the latest transaction made, Concord Wealth Partners holds 671 shares of AZN stock, worth $55,840. This represents 0.01% of its overall portfolio holdings.
Number of Shares
671
Previous 2,180
69.22%
Holding current value
$55,840
Previous $160,000
71.25%
% of portfolio
0.01%
Previous 0.03%
Shares
16 transactions
Others Institutions Holding AZN
# of Institutions
1,439Shares Held
498MCall Options Held
7.22MPut Options Held
2.57M-
Price T Rowe Associates Inc Baltimore, MD51.9MShares$4.32 Billion0.41% of portfolio
-
Primecap Management CO Pasadena, CA41.2MShares$3.43 Billion2.35% of portfolio
-
Wellington Management Group LLP Boston, MA34.3MShares$2.86 Billion0.45% of portfolio
-
Capital International Investors Los Angeles, CA31.4MShares$2.61 Billion0.39% of portfolio
-
Bank Of America Corp Charlotte, NC31.2MShares$2.59 Billion0.16% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $258B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...